Corporate Presentation (TSX: BLU)

FALL 2013

Roberto Bellini
President and Chief Executive Officer
Twitter: @rbellini
Forward Looking Statement

Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the ability to obtain financing immediately in current markets, the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceuticals industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, achievement of forecasted burn rate, and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed.

Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Company's public filings including the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business.
30 million people in the United States have a RARE disease.

Source: NIH: National Institutes of Health Office of Rare Diseases
Only about 5% of these people have a specific therapy to treat their disease.
85-90% of rare diseases are serious or life threatening.
Small patient numbers, Big opportunity

- Regulatory advantage
- Premium pricing
- Market protection
- Smaller clinical trials
- Efficient commercialization strategies
At BELLUS, we are focused on developing drugs for rare diseases starting with conditions that affect the kidneys.
OVERVIEW

- Public company (TSX: BLU) based in Montreal, QC
- Developing drugs for rare diseases
- Late-stage product pipeline with fully funded business plan

CAP STRUCTURE

- Shares outstanding (Fully Diluted): 65M
- Cash\(^1\) (06/30/13): ~$17M
- Burn rate (monthly): <$300K
- Shareholder makeup: 70% institutional, 30% retail

Operations funded into mid-2018

\(^1\)Pro forma Thallion acquisition
## Pipeline of Products

<table>
<thead>
<tr>
<th></th>
<th>DISCOVERY</th>
<th>PRECLINICAL</th>
<th>PHASE I</th>
<th>PHASE II</th>
<th>PHASE III</th>
<th>MARKET</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIACTA™ AA amyloidosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shigamabs sHUS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Non-core assets in memory protection (nutraceutical generating cashflow) and Alzheimer’s disease (Phase 1)
Lead Phase III Product Candidate

FOR AMYLOID A (AA) AMYLOIDOSIS

A rare and deadly kidney disease with no specific treatment
**Disease and Mechanism of Action**

**SERUM AMYLOID A PRECURSOR (SAA) PROTEIN**

**AA PROTEIN + GLYCOSAMINOGLYCANS (GAGs)**

**REDUCTION IN FIBRIL FORMATION & DEPOSITION**

KIACTA blocks AA + GAGs interaction

**CHRONIC INFLAMMATION**

- Generates cytokine cascade (TNFα / IL-1 / IL-6) and increases SAA levels

- Conversts to AA Protein

Rheumatic Conditions
Inflammatory Bowel Disease
Chronic Infections
Familial Mediterranean Fever

Systemic Amyloid A Fibril Formation & Deposition

ORGAN DAMAGE, IN PARTICULAR TO KIDNEYS LEADING TO DIALYSIS
KIACTA™ peak annual revenues projected at $400-600 million¹

- Patient population approximately 34,000-50,000 in the United States, Europe Top 5 and Japan¹
- Strong potential for premium pricing
- Market exclusivity through orphan drug designation (7-10 years) and intellectual property (up to 2031)

¹Market assessment by Frankel Group (April 2009)
PARTNERSHIP

- With global fund Auven Therapeutics, private equity group specialized in drug development project financing

- Auven Therapeutics funding 100% of KIACTA™’s Phase III Confirmatory Study

FINANCIAL IMPLICATION

- US$10M in upfront by Auven Therapeutics

- ≥ US$50M in investments by Auven Therapeutics

- Proceeds of eventual exit expected to be shared 50-50

Partnership to fund Phase III Confirmatory Study with significant upside for BELLUS shareholders
Strong Clinical Results in First Phase III Study

- Landmark study in AA Amyloidosis: 183 patients treated for 2 years
- Important benefits for patients on drug:
  - Statistically significant reduction in number and risk of reaching worsening kidney event
  - Important delay in reaching dialysis
2007 NEJM publication by concludes that KIACTA™ slows decline of renal function in AA Amyloidosis

Agreement reached with FDA, EMEA and Japanese PMDA to conduct Phase III Confirmatory Study

Approval based on achieving comparable result of first Phase III Study
Phase III Confirmatory Study

230 patients in ~25 countries
150+ of 230 patients enrolled
Trial to complete when 120 of 230 patients reach event of kidney function deterioration
Expected to be completed in 2017
Second Rare Disease Product Candidate

FOR STEC RELATED HEMOLYTIC UREMIC SYNDROME (sHUS),
A rare disease primarily affecting the kidneys of children
**Disease Course and Treatment**

**STEC AND sHUS DISEASE COURSE**

- **E. Coli infection**
  - Colonization & toxin production
  - Bloody diarrhea fever

**SHIGAMABS TREATMENT**
- Monoclonal antibody neutralizes toxin
- Expected to improve outcomes including reduced need for dialysis

**90-95%**
- Self-resolution

**5-10%**
- STEC related Hemolytic Uremic Syndrome (sHUS)
  - Dialysis
  - Chronic Kidney Disease
  - Death
MARKET OPPORTUNITY
- 1,500-2,000 estimated annual cases of sHUS in developed countries, principally children
- $100-200 million market opportunity

CLINICAL
- Safe and well tolerated in target pediatric population

NEXT STEPS (12 MONTHS)
- Proof of concept for treatment of sHUS in mouse and primate models
- Meetings with regulators to agree on development plan

Potential for partnership in 18-24 months
Non-Core Assets

**VIVIMIND™**
- Commercial nutraceutical approved for memory protection
- Growing cash flow positive business with ~$450K in revenue last year

**BLU8449**
- Phase I anti-amyloid product targeting Alzheimer’s disease
- Partnered with Asclepios BioResearch

Non-core assets with potential upside for shareholders
# Governance and Shareholders

<table>
<thead>
<tr>
<th>Board of Directors</th>
<th>Company / Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Francesco Bellini (Chair)</td>
<td>[Company Logo]</td>
</tr>
<tr>
<td>Franklin Berger</td>
<td>JPMorgan</td>
</tr>
<tr>
<td>Charles Cavell</td>
<td>[Company Logo]</td>
</tr>
<tr>
<td>Hélène Fortin</td>
<td>LAROSE FORTIN CA Inc.</td>
</tr>
<tr>
<td>Pierre Larochelle</td>
<td>[Company Logo]</td>
</tr>
<tr>
<td>Donald Olds</td>
<td>Presagia</td>
</tr>
<tr>
<td>Joseph Rus</td>
<td>[Company Logo]</td>
</tr>
<tr>
<td>Dr. Martin Tolar</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Roberto Bellini</td>
<td>Bellus Health</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Management</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roberto Bellini</td>
<td>President and Chief Executive Officer</td>
</tr>
<tr>
<td>Dr. Denis Garceau</td>
<td>Senior Vice President, Drug Development</td>
</tr>
<tr>
<td>François Desjardins</td>
<td>Vice President, Finance</td>
</tr>
<tr>
<td>Tony Matzouranis</td>
<td>Vice President, Business Development</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Shareholder</th>
<th>Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bellini Family</td>
<td>≈ 30%</td>
</tr>
<tr>
<td>Power Corporation</td>
<td>≈ 30%</td>
</tr>
<tr>
<td>Pharmascience</td>
<td>≈ 10%</td>
</tr>
</tbody>
</table>
Milestones

Past Execution
- Attractive partnership with for Kiacta
- Execution of global KIACTA Phase III Confirmatory Study
- Acquisition of Shigamabs program
- Strong balance sheet and clean capital structure

Milestones (12 months)
- Completion of recruitment of KIACTA™ Phase III Confirmatory Study
- Additional KIACTA™ activities:
  - Launch of open label extension study
  - Market and pricing assessment
  - Japan orphan drug designation
- Divestiture of non-core assets
- Expand early stage pipeline for rare diseases

Long Term Value
- KIACTA™ exit and results of Phase III Confirmatory Study
- Shigamabs partnership or proof-of-concept Phase II study

Short-term milestones driving long-term value